We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Acorda Therapeutics

News List

Acorda Therapeutics Announces FDA Approval of INBRIJA americanpharmaceuticalreview
January 11, 2019
Acorda Therapeutics announced the U.S. Food and Drug Administration (FDA) approved INBRIJA for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with carbidopa/levodopa.....
FDA extends review of filing for Acorda's Inbrija in Parkinson's disease firstwordpharma
September 14, 2018
Acorda Therapeutics reported Thursday that the FDA extended its review of a filing seeking clearance of Inbrija (levodopa) by three months to January 5, 2019.
Struggling Acorda considering a Sale leads to jump of share biospace
January 09, 2018
Rumors that Acorda Therapeutics was considering a sale drove company stock up about 12 percent on Friday, Jan. 5, to hit $23.55. The Wall Street Journal reported that Acorda had brought in advisers to assist in exploring an auction.
FDA refuses Acorda NDA for Parkinson's drug candidate because of manufacturing issues fiercepharma
August 30, 2017
Acorda Therapeutics has received an FDA Refusal To File letter tied to manufacturing for its Parkinson's disease drug candidate.